Immune phagocytosis inhibition by commercial immunoglobulins

Neppert, J.; Clemens, Mark W.; Mueller-Eckhardt, C

doi:10.1007/bf00321069

Cited by 24 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirty grams of IVIG (Endobulin@, Immuno, Heidelberg, FRG) equivalent to 0.5-0.6 g/kg body weight, were slowly infused over 2-3 h. Subsequent infusions of 20 g of IVIG (0.3-0.4 g/kg) were given every 3 weeks. In the majority of cases treatof Neppert et al [16] who showed that almost all IVIG ment was terminated by gestational week 22-24 (table 1). HLA-A, -B, -C, -DR, -DQ antigens in common with partner.…”

Section: Regimen Of Wig Treatmentmentioning

confidence: 96%

Prevention of Recurrent Spontaneous Abortion by Intravenous Immunoglobulin

et al. 1989

View full text Add to dashboard Cite

Intravenous immunoglobulin (IVIG) treatment was attempted as a novel therapeutic approach for unexplained recurrent spontaneous abortions (RSA) occurring in the first trimester of pregnancy. Twenty women with a history of RSA were treated with IVIG during pregnancy. Therapy was commenced at week 5 of gestation with 1 dose of 0.5-0.6 g IVIG/kg body weight. Infusions were repeated every 3 weeks (0.3-0.4 g/kg) and terminated by week 22 to 24. Of 20 women, 11 delivered healthy infants at term. 5 women are still pregnant, 3 in the third trimester. Only 3 patients suffered abortions and 1 presented with ectopic pregnancy. The overall success rate was 82-86%. Thus, the therapeutic effect of IVIG is comparable to that of the conventional transfusion/vaccination regimen with allogeneic leukocytes, but avoids the risk of transmission of infections and/or HLA immunization, has no major adverse effects and is applicable to 'nonresponders'.

show abstract

Section: Regimen Of Wig Treatmentmentioning

confidence: 96%

Prevention of Recurrent Spontaneous Abortion by Intravenous Immunoglobulin

et al. 1989

View full text Add to dashboard Cite

show abstract

“…Es wurde daher angenommen, daû sie ebenfalls Antikörper gleicher Spezifität enthalten und somit im Sinne einer ¹passiven Immunisierungª gleiche Wirkungen entfalten. Diese Hypothese wurde durch den Nachweis blockierender Aktivität in nahezu allen Immunglobulinpräparaten unterstützt (Neppert et al 1986). Eine erste Pilotstudie publizierten Mueller- Eckhardt (1989).…”

Section: Passive Immuntherapieunclassified

Immune therapy of recurrent abortion

Hinney

Neumeyer

1999

Reproduktionsmedizin

View full text Add to dashboard Cite

“…Die Hemmung der Immunphagozytose mag auch eine Rolle in der Therapie mit hoch dosierten Gaben von Irnmunglobulinen spielen, welche die pathologisch niedrige Thrombozytenzahl bei der Autoimmunthrombozytopenie anheben. In den für diese Therapie verwendeten Immunglobulinpräparaten haben wir Immunphagozytose-hemmende zytotoxisch nicht nachweisbare HLA-Antikörper beobachtet (22). Auch hier legen wir die Hypothese vor, daß diese HLA-Antikörper in vivo die Fc-Rezeptoren der Zellen im retikuloendothelialen System blockieren oder beseitigen.…”

Section: Leukozytäre Antikörperunclassified

Übersichten

1990

LaboratoriumsMedizin

View full text Add to dashboard Cite

The serology of HLA is of high importance in transplantation as well as transfusion medicine, in diseases which are HLA-associated and in forensic medicine. Serological problems are present, since the leucocyte antibodies from different samples vary in respect of their properties in spite of the same specificity. In addition, the antibodies from different samples which react wih the same cell type, e. g. granulocytes, may reveal various specificities. Therefore, presently available methods are described which enable us to discriminate these antibodies. Crosslinkage of Fc-receptors of type I on monocytes and macrophages with HLA-antigens through HLA-antibodies has been recently observed. From this finding a simple and sensitive new technique was developed which detects non-cytotoxic and cytotoxic HLA-antibodies. The mechanism of crosslinkage of molecules corresponds to the phenomenon of immune phagocytosis inhibition' in regard to cell function. This type of inhibition probably is generated in -fetal cells of the placenta and the fetus, if the mother produces HLA-antibodies against it. This is interpreted to be shelter of the fetus against an immunologically aggressive mother. The hypothesis is put forward that immune phagocytosis inhibition in the cells of the reticulo-endothelial system, due to inhibitory HLA-antibodies in commercial immunoglobulins, is the mechanism of effective treatment of the autoimmune thrombocytopenia with these immunoglobulins. Among antibodies specific for non-HLA-antigens we distinguish clinically insignificant, at low temperature active autoantibodies to various types of leucocytes from pathogenetically relevant granulocyte antibodies which cause autoimmune neutropenia or neonatal alloimmune neutropehia. Leucocyte antibodies are described which can induce a severe non-cardiogenic pulmonary oedema after transfusion. In most instances, these antibodies were detected in donor blood components.

show abstract

Immune phagocytosis inhibition by commercial immunoglobulins

Cited by 24 publications

References 20 publications

Prevention of Recurrent Spontaneous Abortion by Intravenous Immunoglobulin

Prevention of Recurrent Spontaneous Abortion by Intravenous Immunoglobulin

Immune therapy of recurrent abortion

Übersichten

Contact Info

Product

Resources

About